Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors

For the Alzheimer's Disease Neuroimaging Initiative, Alzheimer Precision Medicine Initiative (APMI)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment. Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times. Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function. Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment.

Original languageEnglish
Article number642
JournalFrontiers in Neurology
Volume9
Issue numberAUG
DOIs
StatePublished - 14 Aug 2018

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Hippocampus
Cognition
Cholinergic Agents
Episodic Memory
Executive Function
Therapeutics
Standard of Care
Cognitive Dysfunction
Basal Forebrain
Patient Selection
Counseling

Keywords

  • Basal forebrain
  • Cholinergic treatment
  • Executive function
  • Hippocampus
  • MRI
  • Memory
  • Prediction

Cite this

For the Alzheimer's Disease Neuroimaging Initiative ; Alzheimer Precision Medicine Initiative (APMI). / Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors. In: Frontiers in Neurology. 2018 ; Vol. 9, No. AUG.
@article{cf6222f48e704ab2b62d3832b3a11252,
title = "Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors",
abstract = "Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment. Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times. Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function. Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment.",
keywords = "Basal forebrain, Cholinergic treatment, Executive function, Hippocampus, MRI, Memory, Prediction",
author = "{For the Alzheimer's Disease Neuroimaging Initiative} and {Alzheimer Precision Medicine Initiative (APMI)} and Teipel, {Stefan J.} and Enrica Cavedo and Harald Hampel and Grothe, {Michel J.} and Aguilar, {Lisi Flores} and Claudio Babiloni and Filippo Baldacci and Norbert Benda and Black, {Keith L.} and Bokde, {Arun L.W.} and Ubaldo Bonuccelli and Karl Broich and Bun, {Ren{\'e} S.} and Francesco Cacciola and Juan Castrillo and Roberto Ceravolo and chiesa, {Patrizia A.} and Olivier Colliot and Coman, {Cristina Maria} and Corvol, {Jean Christophe} and Cuello, {Augusto Claudio} and Herman Depypere and Bruno Dubois and Andrea Duggento and Stanley Durrleman and Valentina Escott-Price and Howard Federoff and Ferretti, {Maria Teresa} and Massimo Fiandaca and Frank, {Richard A.} and Francesco Garaci and Remy Genthon and Nathalie George and Giorgi, {Filippo S.} and Manuela Graziani and Marion Haberkamp and Habert, {Marie Odile} and Karl Herholz and Eric Karran and Kim, {Seung H.} and Yosef Koronyo and Maya Koronyo-Hamaoui and Foudil Lamari and Todd Langevin and St{\'e}phane Leh{\'e}ricy and Simone Lista and Jean Lorenceau and Mark Mapstone and Christian Neri and Robert Nistic{\`o}",
year = "2018",
month = "8",
day = "14",
doi = "10.3389/fneur.2018.00642",
language = "English",
volume = "9",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Media S.A.",
number = "AUG",

}

Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors. / For the Alzheimer's Disease Neuroimaging Initiative; Alzheimer Precision Medicine Initiative (APMI).

In: Frontiers in Neurology, Vol. 9, No. AUG, 642, 14.08.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors

AU - For the Alzheimer's Disease Neuroimaging Initiative

AU - Alzheimer Precision Medicine Initiative (APMI)

AU - Teipel, Stefan J.

AU - Cavedo, Enrica

AU - Hampel, Harald

AU - Grothe, Michel J.

AU - Aguilar, Lisi Flores

AU - Babiloni, Claudio

AU - Baldacci, Filippo

AU - Benda, Norbert

AU - Black, Keith L.

AU - Bokde, Arun L.W.

AU - Bonuccelli, Ubaldo

AU - Broich, Karl

AU - Bun, René S.

AU - Cacciola, Francesco

AU - Castrillo, Juan

AU - Ceravolo, Roberto

AU - chiesa, Patrizia A.

AU - Colliot, Olivier

AU - Coman, Cristina Maria

AU - Corvol, Jean Christophe

AU - Cuello, Augusto Claudio

AU - Depypere, Herman

AU - Dubois, Bruno

AU - Duggento, Andrea

AU - Durrleman, Stanley

AU - Escott-Price, Valentina

AU - Federoff, Howard

AU - Ferretti, Maria Teresa

AU - Fiandaca, Massimo

AU - Frank, Richard A.

AU - Garaci, Francesco

AU - Genthon, Remy

AU - George, Nathalie

AU - Giorgi, Filippo S.

AU - Graziani, Manuela

AU - Haberkamp, Marion

AU - Habert, Marie Odile

AU - Herholz, Karl

AU - Karran, Eric

AU - Kim, Seung H.

AU - Koronyo, Yosef

AU - Koronyo-Hamaoui, Maya

AU - Lamari, Foudil

AU - Langevin, Todd

AU - Lehéricy, Stéphane

AU - Lista, Simone

AU - Lorenceau, Jean

AU - Mapstone, Mark

AU - Neri, Christian

AU - Nisticò, Robert

PY - 2018/8/14

Y1 - 2018/8/14

N2 - Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment. Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times. Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function. Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment.

AB - Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment. Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times. Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function. Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment.

KW - Basal forebrain

KW - Cholinergic treatment

KW - Executive function

KW - Hippocampus

KW - MRI

KW - Memory

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=85051623039&partnerID=8YFLogxK

U2 - 10.3389/fneur.2018.00642

DO - 10.3389/fneur.2018.00642

M3 - Article

AN - SCOPUS:85051623039

VL - 9

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - AUG

M1 - 642

ER -